Antisense phosphorothioate oligodeoxynucleotides: introductory concepts and possible molecular mechanisms of toxicity
Identifieur interne : 004104 ( Main/Exploration ); précédent : 004103; suivant : 004105Antisense phosphorothioate oligodeoxynucleotides: introductory concepts and possible molecular mechanisms of toxicity
Auteurs : Gerald Zon [États-Unis]Source :
- Toxicology Letters [ 0378-4274 ] ; 1995.
English descriptors
- Teeft :
- Alternative mode, Analog, Antisense, Antisense agent, Antisense agents, Antisense compounds, Antisense oligonucleotide, Antisense oligonucleotide analog, Antisense oligonucleotides, Antisense phosphorothioate oligodeoxynucleotides, Cellular uptake, Complementary sequence, Drug development, Drug discovery, Genetic expression, Hybridization, Interception process, Marrow purge, Nucleic acids, Oligodeoxynucleotide, Oligodeoxynucleotides, Oligonucleotide, Oligonucleotides, Pennsylvania cancer center, Personal communication, Phosphorothioate, Phosphorothioate oligodeoxynucleotides, Phosphorothioate oligonucleotides, Potential advantage, Recent reviews, Therapeutic agents, Toxicity, Toxicology, Toxicology letters.
Abstract
Abstract: Over the past 5 years or so, much attention has been given to the possible use of synthetic antisense oligonucleotide analogs as a new class of therapeutic agents that function by sequence-specific inhibition of genetic expression. The basic design concepts which underline this novel approach to drug discovery are briefly described herein, together with some of the chemical, biochemical, and pharmacological aspects of phosphorothioate oligodeoxynucleotides that are first-generation antisense compounds now under clinical investigation. Possible molecular mechanisms of toxicity for this class, and other structural types of antisense compounds are discussed with the hope of stimulating interest in future toxicological studies in this emerging area of drug development.
Url:
DOI: 10.1016/0378-4274(95)03571-0
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000498
- to stream Istex, to step Curation: 000498
- to stream Istex, to step Checkpoint: 001795
- to stream Main, to step Merge: 004165
- to stream Main, to step Curation: 004104
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Antisense phosphorothioate oligodeoxynucleotides: introductory concepts and possible molecular mechanisms of toxicity</title><author><name sortKey="Zon, Gerald" sort="Zon, Gerald" uniqKey="Zon G" first="Gerald" last="Zon">Gerald Zon</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:64718481A3C543F7B063815D467E033DD3601AC1</idno><date when="1995" year="1995">1995</date><idno type="doi">10.1016/0378-4274(95)03571-0</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-GZ6DCV18-K/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000498</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000498</idno><idno type="wicri:Area/Istex/Curation">000498</idno><idno type="wicri:Area/Istex/Checkpoint">001795</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001795</idno><idno type="wicri:doubleKey">0378-4274:1995:Zon G:antisense:phosphorothioate:oligodeoxynucleotides</idno><idno type="wicri:Area/Main/Merge">004165</idno><idno type="wicri:Area/Main/Curation">004104</idno><idno type="wicri:Area/Main/Exploration">004104</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Antisense phosphorothioate oligodeoxynucleotides: introductory concepts and possible molecular mechanisms of toxicity</title><author><name sortKey="Zon, Gerald" sort="Zon, Gerald" uniqKey="Zon G" first="Gerald" last="Zon">Gerald Zon</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Lynx Therapeutics, Inc., 3832 Bay Center Place, Hayward, CA 94545</wicri:regionArea><wicri:noRegion>CA 94545</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Toxicology Letters</title><title level="j" type="abbrev">TOXLET</title><idno type="ISSN">0378-4274</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1995">1995</date><biblScope unit="volume">82–83</biblScope><biblScope unit="supplement">C</biblScope><biblScope unit="page" from="419">419</biblScope><biblScope unit="page" to="424">424</biblScope></imprint><idno type="ISSN">0378-4274</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0378-4274</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Alternative mode</term><term>Analog</term><term>Antisense</term><term>Antisense agent</term><term>Antisense agents</term><term>Antisense compounds</term><term>Antisense oligonucleotide</term><term>Antisense oligonucleotide analog</term><term>Antisense oligonucleotides</term><term>Antisense phosphorothioate oligodeoxynucleotides</term><term>Cellular uptake</term><term>Complementary sequence</term><term>Drug development</term><term>Drug discovery</term><term>Genetic expression</term><term>Hybridization</term><term>Interception process</term><term>Marrow purge</term><term>Nucleic acids</term><term>Oligodeoxynucleotide</term><term>Oligodeoxynucleotides</term><term>Oligonucleotide</term><term>Oligonucleotides</term><term>Pennsylvania cancer center</term><term>Personal communication</term><term>Phosphorothioate</term><term>Phosphorothioate oligodeoxynucleotides</term><term>Phosphorothioate oligonucleotides</term><term>Potential advantage</term><term>Recent reviews</term><term>Therapeutic agents</term><term>Toxicity</term><term>Toxicology</term><term>Toxicology letters</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Over the past 5 years or so, much attention has been given to the possible use of synthetic antisense oligonucleotide analogs as a new class of therapeutic agents that function by sequence-specific inhibition of genetic expression. The basic design concepts which underline this novel approach to drug discovery are briefly described herein, together with some of the chemical, biochemical, and pharmacological aspects of phosphorothioate oligodeoxynucleotides that are first-generation antisense compounds now under clinical investigation. Possible molecular mechanisms of toxicity for this class, and other structural types of antisense compounds are discussed with the hope of stimulating interest in future toxicological studies in this emerging area of drug development.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country></list><tree><country name="États-Unis"><noRegion><name sortKey="Zon, Gerald" sort="Zon, Gerald" uniqKey="Zon G" first="Gerald" last="Zon">Gerald Zon</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004104 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004104 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:64718481A3C543F7B063815D467E033DD3601AC1
|texte= Antisense phosphorothioate oligodeoxynucleotides: introductory concepts and possible molecular mechanisms of toxicity
}}
| This area was generated with Dilib version V0.6.33. |  |